Table 1.
Baseline characteristics of participants who had baseline data and at least one follow-up visit.
| Ingestible sensor (N = 54) |
Usual care (N = 58) |
Total (N = 112) |
|
|---|---|---|---|
| Age - mean years (SD) | 46.7 (11.1) | 45.7 (12.4) | 46.2 (11.8) |
| Gender - N (%) | |||
| Female | 5 (9.3%) | 5 (8.6%) | 10 (8.9%) |
| Male | 44 (81.5%) | 43 (74.1%) | 87 (77.7%) |
| Transgender: Male to Female | 5 (9.3%) | 10 (17.2%) | 15 (13.4%) |
| Race and ethnicity - N (%) | |||
| White | 6 (11.1%) | 8 (13.8%) | 14 (12.5%) |
| Black | 24 (44.4%) | 30 (51.7%) | 54 (48.2%) |
| Latino | 19 (35.2%) | 16 (27.6%) | 35 (31.2%) |
| Asian | 1 (1.9%) | 1 (1.7%) | 2 (1.8%) |
| Other | 4 (7.4%) | 3 (5.2%) | 7 (6.3%) |
| Education - N (%) | |||
| 8th grade or less/Some high school but did not graduate | 8 (14.8%) | 10 (17.2%) | 18 (16.1%) |
| High school graduate/Some college but no degree | 38 (70.4%) | 39 (67.2%) | 77 (68.8%) |
| Completed college/More than four-year college degree | 8 (14.8%) | 9 (15.5%) | 17 (15.2%) |
| Employment - N (%) | |||
| Part-time/full-time | 9 (16.7%) | 19 (32.8%) | 28 (25.0%) |
| None/full-time student/retired/disabled | 45 (83.3%) | 39 (67.2%) | 84 (75.0%) |
| HIV + Years - median (IQR) | 14.5 (12.5) | 11.0 (14.0) | 13.5 (13.0) |
| Years under ARV Treatment - median (IQR) | 12.5 (11.5) | 10.0 (9.8) | 10.0 (11.5) |
| History of AIDS Diagnosis - N (%) | |||
| Yes | 12 (22.2%) | 12 (20.7%) | 24 (21.4%) |
| No | 42 (77.8%) | 46 (79.3%) | 88 (78.6%) |
| Detectable VL at Baseline - N (%) | |||
| Less than 50 copies/mL | 35 (64.8%) | 46 (79.3%) | 81 (72.3%) |
| Greater than 50 copies/mL | 19 (35.2%) | 12 (20.7%) | 31 (27.7%) |
| VL (week 0) in Log Scale - median (IQR)a | 1.7 (0.3) | 1.7 (0.0) | 1.7 (0.1) |
| CD4 Cell Count at Baseline (cells/mm3) - mean (SD) | 522.4 (284.4) | 530.5 (283.6) | 526.6 (282.7) |
| Self-reported Adherence (week 0) - mean (SD) | 0.9 (0.1) | 0.9 (0.1) | 0.9 (0.1) |
| Current ARV Treatmentb- N (%) | |||
| Single tablet regimens | 39 (72.2%) | 35 (60.3%) | 74 (66.1%) |
| BIC/FTC/TAF | 16 (29.6%) | 17 (29.3%) | 33 (29.5%) |
| 3TC/ABC/DTG | 6 (11.1%) | 8 (13.8%) | 14 (12.5%) |
| EVG/COBI/FTC/TAF | 8 (14.8%) | 6 (10.3%) | 14 (12.5%) |
| FTC/RPV/TAF | 7 (13.0%) | 3 (5.2%) | 10 (8.9%) |
| TDF/FTC/EFV | 2 (3.7%) | 1 (1.7%) | 3 (2.7%) |
| Multiple tablet regimens | 15 (27.8%) | 23 (39.7%) | 38 (33.9%) |
| FTC/TAF + DRV/COBI | 9 (16.7%) | 5 (8.6%) | 14 (12.5%) |
| FTC/TAF + DTG | 1 (1.9%) | 6 (10.3%) | 7 (6.3%) |
| FTC/TAF + DRV + RTV | 1 (1.9%) | 2 (3.4%) | 3 (2.7%) |
| FTC/TDF + DRV/COBI | 0 (0.0%) | 3 (5.2%) | 3 (2.7%) |
| FTC/TAF + ATV/COBI | 1 (1.9%) | 2 (3.4%) | 3 (2.7%) |
| FTC/TDF + DRV + RTV | 0 (0.0%) | 2 (3.4%) | 2 (1.8%) |
| FTC/RPV/TAF + DTG | 1 (1.9%) | 0 (0.0%) | 1 (0.9%) |
| FTC/TDF + DTG | 0 (0.0%) | 1 (1.7%) | 1 (0.9%) |
| 3TC/ABC + DRV + RTV | 1 (1.9%) | 0 (0.0%) | 1 (0.9%) |
| 3TC/ABC + EFV | 1 (1.9%) | 0 (0.0%) | 1 (0.9%) |
| FTC/RPV/TAF + DTG + DRV/COBI | 0 (0.0%) | 1 (1.7%) | 1 (0.9%) |
| FTC/TAF + DTG + DRV/COBI | 0 (0.0%) | 1 (1.7%) | 1 (0.9%) |
VL, viral load; SD, standard deviation; IQR, interquartile range.
a
For patients with undetectable HIV RNA plasma, viral load were all treated as 50 copies/mL.
b
ARV, antiretroviral; ABC, abacavir; ATV, atazanavir; BIC, bictegravir; COBI, cobicistat; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; RPV, rilpivirine; RTV, ritonavir; 3 TC, lamivudine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.